Richard Theolis

20100143368, Jun 10, 2010

Nov 30, 2007

12/517183

David John King - Solana Beach CA, US
Alison Witte - Scotts Valley CA, US
Heidi N. LeBlanc - Mountain View CA, US
Richard Theolis - Santa Cruz CA, US
Asna Masood - Saratoga CA, US
Mark Yamanaka - Pleasanton CA, US
Kyra D. Emory - Mountain View CA, US
Sarah R. Reed - Santa Cruz CA, US
Tim Sproul - Livermore CA, US
David Passmore - San Carlos CA, US

A61K 39/395
C07K 16/28
A61P 29/00
A61P 37/06
A61P 35/00
C12N 5/00

4241421, 53038815, 5303917, 5303913, 4241781, 435375

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

20110182904, Jul 28, 2011

Sep 5, 2007

12/440000

Deborah Zimmerman - Oakland CA, US
Mark Selby - San Francisco CA, US
Mohan Srinivasan - San Jose CA, US
Alasdair Bell - Mountain View CA, US
Sujata Singh - Saratoga CA, US
Richard Theolis - Santa Cruz CA, US
Heidi N. Leblanc - Mountain View CA, US
Kyra D. Zens - San Mateo CA, US
Timothy William Sproul - Livermore CA, US

A61K 39/395
C07K 16/22
A61P 19/08
A61P 35/00
C12N 15/13
C12N 15/63
C12N 5/00
C12P 21/08

4241451, 53038823, 5303873, 5303911, 5303917, 5303913, 536 2353, 4353201, 435325, 435 696, 800 4

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.

20130230530, Sep 5, 2013

Feb 20, 2013

13/772063

Alison Witte - Scotts Valley CA, US
Heidi N. Leblanc - Mountain View CA, US
Richard Theolis - Santa Cruz CA, US
Asna Masood - Saratoga CA, US
Mark Yamanaka - Pleasanton CA, US
Kyra D. Zens - San Mateo CA, US
Sarah R. Reed - Sanat Cruz CA, US
Tim Sproul - Livermore CA, US
David Passmore - Mountain View CA, US
Dawn M. Tanamachi - San Carlos CA, US
Kristopher Toy - San Jose CA, US

Medarex, Inc. - Princeton NJ

C07K 16/30
A61K 45/06
A61K 39/395

4241391, 435375, 4241781, 4241791

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

20210000952, Jan 7, 2021

Jun 17, 2020

16/904511

- Holon, IL
Sandeep Kumar - San Bruno CA, US
Christopher Chan - South San Francisco CA, US
Spencer Liang - San Mateo CA, US
Lance Stapleton - Oakland CA, US
Andrew W. Drake - Mountain View CA, US
Yosi Gozlan - Tel Aviv, IL
Ilan Vaknin - Tel Aviv, IL
Shirley Sameah-Greenwald - Kfar Saba, IL
Liat Dassa - Tel Aviv, IL
Zohar Tiran - Oranit, IL
Gad S. Cojocaru - Tel Aviv, IL
Maya Kotturi - Belmont CA, US
Hsin-Yuan Cheng - San Mateo CA, US
Kyle Hansen - San Francisco CA, US
David Nisim Giladi - Netaniya, IL
Einav Safyon - Raanana, IL
Eran Ophir - Even Yehuda, IL
Leonard Presta - San Francisco CA, US
Richard Theolis - Santa Cruz CA, US
Radhika Desai - Brisbane CA, US
Patrick Wall - Mill Valley CA, US

A61K 39/395
C07K 16/28
A61P 35/00

Anti-PVRIG and anti-TIGIT antibodies are provided.

20190352426, Nov 21, 2019

Aug 2, 2017

16/322417

- South San Francisco CA, US
Christopher E. HENRY - San Carlos CA, US
Richard THEOLIS - Santa Cruz CA, US
Shuang WU - South San Francisco CA, US

Achaogen, Inc. - South San Francisco CA

C07K 16/44
A61K 47/64
G01N 33/53

The present invention provides anti-plazomicin antibodies and methods of use thereof, e.g., in determining levels of plazomicin in samples from human patients undergoing treatment with plazomicin. Such antibodies are useful, for example, in monitoring plazomicin levels during treatment for an infectious disease.

20180305456, Oct 25, 2018

Aug 17, 2017

15/680187

Mark White - Antioch CA, US
Sandeep Kumar - San Bruno CA, US
Christopher Chan - South San Francisco CA, US
Spencer Liang - San Mateo CA, US
Lance Stapleton - Oakland CA, US
Andrew W. Drake - Mountain View CA, US
Yosi Gozlan - Tel Aviv, IL
Ilan Vaknin - Tel Aviv, IL
Shirley Sameah-Greenwald - Kfar Saba, IL
Liat Dassa - Tel Aviv, IL
Zohar Tiran - Oranit, IL
Gad S. Cojocaru - Tel Aviv, IL
Maya Kotturi - Belmont CA, US
Hsin-Yuan Cheng - San Mateo CA, US
Kyle Hansen - San Francisco CA, US
David Nisim Giladi - Netaniya, IL
Einav Safyon - Raanana, IL
Eran Ophir - Even Yehuda, IL
Leonard Presta - San Francisco CA, US
Richard Theolis - Santa Cruz CA, US
Radhika Desai - Brisbane CA, US
Patrick Wall - Mill Valley CA, US

C07K 16/28
A61P 35/00

Anti-PVRIG and anti-TIGIT antibodies are provided.

20180280506, Oct 4, 2018

Mar 27, 2018

15/937784

- Holon, IL
Sandeep Kumar - San Bruno CA, US
Christopher Chan - South San Francisco CA, US
Spencer Liang - San Mateo CA, US
Lance Stapleton - Oakland CA, US
Andrew W. Drake - Mountain View CA, US
Yosi Gozlan - Tel Aviv, IL
Ilan Vaknin - Tel Aviv, IL
Shirley Sameah-Greenwald - Kfar Saba, IL
Liat Dassa - Tel Aviv, IL
Zohar Tiran - Oranit, IL
Gad S. Cojocaru - Tel Aviv, IL
Maya Kotturi - Belmont CA, US
Hsin-Yuan Cheng - San Mateo CA, US
Kyle Hansen - San Francisco CA, US
David Nisim Giladi - Netaniya, IL
Einav Safyon - Raanana, IL
Eran Ophir - Even Yehuda, IL
Leonard Presta - San Francisco CA, US
Richard Theolis - Santa Cruz CA, US
Radhika Desai - Brisbane CA, US
Patrick Wall - Mill Valley CA, US

A61K 39/395
C07K 16/28
A61K 39/00

Anti-PVRIG and anti-TIGIT antibodies are provided.

20180244774, Aug 30, 2018

Feb 13, 2018

15/896040

- Holon, IL
Sandeep Kumar - San Bruno CA, US
Christopher Chan - South San Francisco CA, US
Spencer Liang - San Mateo CA, US
Lance Stapleton - Oakland CA, US
Andrew W. Drake - Mountain View CA, US
Yosi Gozlan - Tel Aviv, IL
Ilan Vaknin - Tel Aviv, IL
Shirley Sameah-Greenwald - Kfar Saba, IL
Liat Dassa - Tel Aviv, IL
Zohar Tiran - Oranit, IL
Gad S. Cojocaru - Tel Aviv, IL
Leonard Presta - San Francisco CA, US
Richard Theolis - Santa Cruz CA, US

C07K 16/28
C07K 7/06
G01N 33/574

The present invention is directed to anti-PVRIG antibodies and methods of using same.